You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Osteoporosis

Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

  • Technology appraisal guidance
  • Reference number: TA160
  • Published:  27 October 2008
  • Last updated:  07 February 2018
  • Guidance
  • Tools and resources
  • Evidence
  • History

Osteoporosis - primary prevention: Court Order, Memorandum of Understanding, background information and matrix of stakeholders for this reconsideration

  • Osteoporosis - primary prevention: Court Order and Memorandum of Understanding

  • Osteoporosis - primary prevention: background to the reconsideration of strontium ranelate

  • Osteoporosis - primary prevention: history of the appraisal development

  • Osteoporosis - primary prevention: guidance for the committee on the reconsideration of strontium ranelate

  • Osteoporosis - primary prevention: final matrix of Consultees and Commentators for the reconsideration of strontium ranelate


This page was last updated: 07 December 2010

Back to top